Compare Abbott Laboratories (ABT) vs Peloton Interactive Inc (PTON) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs Peloton Interactive Inc — how do they compare? Abbott Laboratories trades at $109.64 (market cap $187.95B), while Peloton Interactive Inc trades at $5.6 (market cap $2.46B). The key difference: Abbott Laboratories is far larger — about 76.4× Peloton Interactive Inc's market cap, and Abbott Laboratories pays a 2.32% dividend while Peloton Interactive Inc pays none. Which is the better fit depends on your goals.
| ABT | PTON | |
|---|---|---|
Market Cap | $187.95B | $2.46B |
Sector | Health | Consumer Cyclical |
52-Week High | $136.62 | $9.00 |
52-Week Low | $82.57 | $3.71 |
Enterprise Value | $214.96B | $2.96B |
Dividend Yield | 2.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.
Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.
Peloton Interactive (PTON) trades at $5.42, down 1.63% today, with a bearish technical signal and negative shareholder equity. The company achieved its first annual net profit in fiscal 2026, with Q4 earnings beating estimates at $0.13 per share. Revenue declined to $2.49 billion in 2025, but net losses narrowed significantly to $119 million. Cash flow turned positive at $335 million, and debt-to-asset ratio improved to 63.18% in 2026. Analyst sentiment is mixed with a 50% buy rating.
Outlook remains cautious due to ongoing revenue declines and high debt, but profitability improvements and cost controls provide a foundation for recovery. Key risks include subscriber losses, competitive pressures, and patent litigation. The stock offers speculative upside if growth stabilizes, but requires careful risk management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Peloton Interactive Inc
Peloton Interactive Inc operates an interactive fitness platform. It operates its business in two reportable segments: Connected Fitness Products and Subscription. Connected Fitness Product revenue consists of sales of bike and tread and related accessories, associated fees for delivery and installation, and extended warranty agreements. Subscription revenue consists of revenue generated from monthly Connected Fitness Subscription and Digital Subscription. The company generates the majority of the revenue from the sale of Connected Fitness Products.
Read more on PTON →
